JP2006520767A5 - - Google Patents

Download PDF

Info

Publication number
JP2006520767A5
JP2006520767A5 JP2006505152A JP2006505152A JP2006520767A5 JP 2006520767 A5 JP2006520767 A5 JP 2006520767A5 JP 2006505152 A JP2006505152 A JP 2006505152A JP 2006505152 A JP2006505152 A JP 2006505152A JP 2006520767 A5 JP2006520767 A5 JP 2006520767A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
disease
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006505152A
Other languages
English (en)
Japanese (ja)
Other versions
JP4572195B2 (ja
JP2006520767A (ja
Filing date
Publication date
Priority claimed from EP03290727A external-priority patent/EP1460075A1/en
Application filed filed Critical
Publication of JP2006520767A publication Critical patent/JP2006520767A/ja
Publication of JP2006520767A5 publication Critical patent/JP2006520767A5/ja
Application granted granted Critical
Publication of JP4572195B2 publication Critical patent/JP4572195B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006505152A 2003-03-21 2004-03-19 8−置換−6,7,8,9−テトラヒドロピリミド[1,2−a]ピリミジン−4−オン誘導体 Expired - Fee Related JP4572195B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290727A EP1460075A1 (en) 2003-03-21 2003-03-21 Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
PCT/EP2004/004014 WO2004082577A2 (en) 2003-03-21 2004-03-19 8-SUBSTITUTED-6, 7, 8, 9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2006520767A JP2006520767A (ja) 2006-09-14
JP2006520767A5 true JP2006520767A5 (https=) 2007-05-10
JP4572195B2 JP4572195B2 (ja) 2010-10-27

Family

ID=32799140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006505152A Expired - Fee Related JP4572195B2 (ja) 2003-03-21 2004-03-19 8−置換−6,7,8,9−テトラヒドロピリミド[1,2−a]ピリミジン−4−オン誘導体

Country Status (25)

Country Link
US (2) US7247638B2 (https=)
EP (2) EP1460075A1 (https=)
JP (1) JP4572195B2 (https=)
KR (1) KR101070149B1 (https=)
CN (1) CN100358897C (https=)
AR (1) AR043658A1 (https=)
AT (1) ATE452892T1 (https=)
AU (1) AU2004222596B2 (https=)
BR (1) BRPI0408591A (https=)
CA (1) CA2518299C (https=)
CY (1) CY1109890T1 (https=)
DE (1) DE602004024770D1 (https=)
DK (1) DK1608654T3 (https=)
EA (1) EA009197B1 (https=)
ES (1) ES2338325T3 (https=)
IL (1) IL170680A (https=)
MX (1) MXPA05010158A (https=)
NO (1) NO20054330L (https=)
NZ (1) NZ542380A (https=)
PL (1) PL1608654T3 (https=)
PT (1) PT1608654E (https=)
SI (1) SI1608654T1 (https=)
TW (1) TWI330186B (https=)
WO (1) WO2004082577A2 (https=)
ZA (1) ZA200507487B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460075A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP1939187A1 (en) * 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
CA3112326A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
KR20250127350A (ko) 2019-09-26 2025-08-26 노파르티스 아게 항바이러스성 피라졸로피리디논 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001270884A (ja) * 2000-03-23 2001-10-02 Mitsubishi-Tokyo Pharmaceuticals Inc ピリミドン誘導体
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EP1184383A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
AR030587A1 (es) * 2000-09-01 2003-08-27 Sanofi Aventis Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)-ona
EP1460075A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives

Similar Documents

Publication Publication Date Title
JP2006520767A5 (https=)
JP2006520766A5 (https=)
RU2653054C2 (ru) Замещенные соединения пиридин азолопиримидин-5-(6н)-она
JP4572195B2 (ja) 8−置換−6,7,8,9−テトラヒドロピリミド[1,2−a]ピリミジン−4−オン誘導体
DE60206946T2 (de) Substituierte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)onderivate gegen neurodegenerative erkrankungen
DE60205921T2 (de) SUBSTITUIERTE 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDOç1,2-A!PYRIMIDIN-4-ON- UND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO-ç1,2-A!PYRIMIDIN-5(1H)ONDERIVATE
EP2388002B1 (en) Antidepressant containing heterocyclic compound having specific structure
JP2010538001A5 (https=)
KR20170066417A (ko) Pde1 억제제로서의 트리아졸로피라지논
JP2005504809A5 (https=)
JP2010526138A (ja) ピロロピリミジン−7−オン誘導体とその薬剤としての使用
RU2007119585A (ru) Производные рапамицина и их применение при лечении неврологических заболеваний
JP2004538268A5 (https=)
DE602004006869T2 (de) 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
WO2006033007A3 (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CN116283877A (zh) 化合物、组合物及其用途
CA2516937A1 (en) Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one derivatives and theiruse against neurogenerative diseases
CA2389553A1 (en) Heteroaryl-diazabicycloalkanes
JP2005504810A5 (https=)
EP1637533A1 (de) Substituierte Thiazolopyrimidine als Analgetika
EP2448942B1 (en) FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS
WO2005044818A2 (en) Imidazo[1,2-a]pyridine anxiolytics
JP2007520525A5 (https=)
JP2023536511A5 (https=)
WO2002060907A1 (en) Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient